Last updated on April 2019

A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors


Brief description of study

The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).

Clinical Study Identifier: NCT03343613

Contact Investigators or Research Sites near you

Start Over

Gustave Roussy

Villejuif Cedex, France
9.91miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.